Seroconversion following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients

Introduction

Protective immunity to SARS-CoV-2, either naturally-induced by infection or artificially-induced or augmented by vaccination, is vital to reducing the transmission of SARS-CoV-2 and the burden of severe COVID-19. Data on the impact of immunomodulatory therapies used to treat inflammatory bowel disease (IBD) on both types of protective immunity have been scant, with initial reports of attenuation of natural immunity and vaccine efficacy by TNF antagonists^1,2. However, two doses of COVID-19 vaccine or a single dose in those with a history of SARS-CoV-2 infection have both been shown to induce seroconversion in a large majority of patients^2,3. There is little data on seroconversion in pediatric IBD, a population that may have distinct immunologic responses to SARS-CoV-2, given that increased age has been associated with lower antibody concentrations post-COVID-19-vaccination². Understanding seroconversion is particularly important as vaccination becomes more widely available in pediatrics with the recent emergency use approval of BNT162b2 (Pfizer-BioNTech) down to 12 years of age⁴. We, therefore, sought to evaluate and compare serologic responses to SARS-CoV-2 infection and vaccination in a pediatric IBD cohort.

Methods

We conducted a retrospective chart review of all IBD patients ≤21 years old in whom a SARS-CoV-2 IgG Antibody Assay was performed between April 2020 and May 2021 at our tertiary care center. The COVID-SeroKlir (Kantaro Biosciences, LLC, New York, NY) semi-quantitative SARS-CoV-2 IgG Antibody Assay, an ELISA measuring IgG antibody to the full-length SARS-CoV-2 spike protein with emergency use authorization, was routinely collected at infusion and outpatient clinic visits⁵. The study was approved by the Mount Sinai Institutional Review Board.

Electronic medical records were reviewed, and data were collected on demographics, IBD location and behavior (Paris classification)⁶, exposure(s) to SARS-CoV-2, and history of SARS-CoV-2 infection/symptoms. Indication for antibody testing and titer levels, which were described as high titer or strongly positive (≥960 titer or >40 AU/mL), moderately positive (320-960 titer or 16-39 AU/mL), weakly positive (80-160 titer or 5-15 AU/mL), and negative,⁵ were recorded. Patients meeting WHO criteria for confirmed (laboratory confirmation of COVID-19 infection) or probable COVID-19 (either meeting defined clinical criteria with contact with a probable or confirmed case of COVID-19 or recent onset of anosmia/ageusia without an identified cause) were classified as having prior COVID-19 infection⁷.

Standard descriptive statistics, including frequency for categorical variables and median [interquartile range (IQR)] for continuous variables, were calculated unless otherwise stated. Univariate analyses were performed using Fisher’s Exact and Chi-Square for categorical variables and Mann-Whitney and Spearman’s Rank Coefficient for continuous variables where appropriate. Statistical analyses were performed using R 3.6.3 (The R Foundation for Statistical Computing, 2018) and SAS OnDemand for Academics 3.8 (SAS Institute Inc., Cary, NC, 2020). P-value <0.05 was considered statistically significant.

Results

One or more SARS-CoV-2 IgG Antibody Assay(s) was performed in 340 pediatric patients; 15% for confirmed or probable COVID-19, 2% for suspected COVID-19, 16% for an exposure to a close contact with SARS-CoV-2 infection without clinical symptoms, 61% without any prior symptoms or exposures, and 6% for history of COVID-19 vaccination. In the 51 patients with confirmed or probable COVID-19, 90% had seroconversion (Supplementary Table 1). Of the five patients without evidence of seroconversion, three had confirmed, and two had probable COVID-19. Those that did not seroconvert were similar in age to the rest of the post-infection cohort (Median 20 [17-20] years, P-value= 0.15) with a trend to a higher proportion of patients with UC/IBD-U (60%, P-value=0.07); four (80%) patients were on a biologic therapy (3 infliximab, 1 ustekinumab) and the remaining patient was on 5-aminosalicylate (5-ASA). There was a significantly longer time interval between infection and titer level measurement in those with a negative titer (Negative: 257 [167-340] days; Positive: 112 [41-180] days; P-value: 0.03); however, titer level was not correlated with time from infection in the entire post-infection cohort (ρ = -0.06, P-value = 0.74).

Within the 16% with exposure to SARS-CoV-2 without clinical symptoms, 23 (43%) had a positive SARS-CoV-2 Antibody Assay. There were no identified clinical characteristics associated with seroconversion in the group exposed to SAR-CoV-2 without clinical symptoms (Supplementary Table 2).

Twenty patients had antibody testing after vaccination (Table 1). All patients seroconverted following vaccination, and all patients receiving mRNA vaccination had high titer levels. The patient who received a single dose of JNJ-78436735 (Johnson & Johnson) had a moderate titer level. All but one (95%) of those receiving a two-series mRNA vaccination had completed both vaccinations in the series; the single patient with an assay performed after only one dose of BNT162b2, with no prior history of SARS-CoV-2 infection, seroconverted. Titer level was not significantly associated with type of biologic or small molecule therapy (Figure 1); patients receiving mRNA-1273 (NIH-Moderna) did have significantly higher titer levels compared to BNT162b2 and JNJ-78436735 (P=0.005).

• Download figure
• Open in new tab

Figure 1

Titer Level by IBD Therapy and Vaccine Type Abbreviations: IFX, infliximab; TOFA, tofacitinib; UST, ustekinumab

Discussion

Herein we report robust serologic antibody responses to SARS-CoV-2 infection and COVID-19 vaccination in a pediatric IBD cohort. All of our patients seroconverted after vaccination even in the setting of biologic and small molecule usage, which was similar to the findings in an adult IBD study published out of our center³. Moreover, nearly all (90%) of our patients had seroconversion following SARS-CoV-2 infection, which was higher than the rates seen in Kennedy et al., suggesting improved post-infection seroconversion in pediatrics¹. The high titer levels achieved in a large number of those who seroconverted are thought to confer protection; however, the association with elapsed time from SARS-CoV-2 exposure to negative level warrants continued investigation into the longevity of the protection conferred as well as a more detailed cataloging of the complexities of the immunoprotective response beyond IgG antibodies. While we are limited by our small sample size and variable times to assay, this study provides important reassurances to pediatric gastroenterologists, patients, and families and lends further support to expert consensus recommendations for vaccination of IBD patients⁸.